Reuters logo
BRIEF-VBL Therapeutics says VB-111 given orphan drug designation in Europe
October 20, 2017 / 1:05 PM / in a month

BRIEF-VBL Therapeutics says VB-111 given orphan drug designation in Europe

Oct 20 (Reuters) - Vascular Biogenics Ltd

* VBL Therapeutics announces orphan drug designation for VB-111 in Europe

* VBL Therapeutics - ‍European Medicines Agency designated ofranergene obadenovec as an “orphan medicinal product” for treatment of ovarian cancer​ Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below